Community/Retail

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Pharmacists are ranked as one of the top most-trusted professions, but what happens when they make mistakes?

With the smart tablets coming to market in 2018, it is a good time to explore how the technology behind the product works.

The holiday presents a great opportunity for pharmacists to help educate patients.

Here are ways for pharmacists to relieve foot and leg aches after a long shift.

A team of researchers have assessed supertherapeutic doses of NSAIDs, opioids, and benzodiazepines.

Officials with the FDA have approved emicizumab-kxwh (Hemlibra, Genentech) as a treatment for patients with hemophilia A who have factor VIII inhibitors, according to a press release from the agency.

Officials with the FDA have approved obinutuzumab (Gazyva, Genentech) in combination with chemotherapy, followed by obinutuzumab alone, for the first-line treatment of patients with advanced follicular lymphoma, according to the company's press release.

In this clip taken at the 2017 American Heart Association Meeting, Robert Carey, MD, of the University of Virginia discusses the expected increases in the population from the 2003 and 2017 guideline recommendations on hypertension.

Speeding up the review of drugs to treat serious diseases makes sense. Here is a look at how it works.

Here is a cheat sheet of the most common prescription drugs for canines.

What role does this medication play in diabetes therapy, and what are its clinical benefits, compared with competitors?

Officials with the FDA today approved the first treatment for mucopolysaccharidosis type VII (MPS VII), a rare genetic enzyme disorder, also called Sly syndrome.

Officials with the FDA have permitted marketing of the first device for use in reducing symptoms of opioid withdrawal.

At the American Heart Association's 2017 Scientific Sessions, Niteesh Kumar Choudhry, MD, PhD, Associate Professor at Harvard Medical School, presented the results of a study that evaluated a technology-enabled intervention conducted by pharmacists to help patients with chronic metabolic conditions adhere to their medications.

At the American Heart Association's 2017 Scientific Sessions, Niteesh Kumar Choudhry, MD, PhD, Associate Professor at Harvard Medical School, explained how pharmacists can use a behaviorally tailored method of patient interviewing to assess patients' adherence barriers.

Officials with the FDA have approved benralizumab (Fasenra, AstraZeneca) for the add-on maintenance treatment of patients with severe eosinophilic asthma aged 12 years and older.

Officials with the FDA have issued a public health advisory on kratom, warning consumers about the potential risks associated with its use.

In this clip, Dr. Whelton discusses the guideline's emphasis on a team-based approach to assessing and treating hypertension in patients.

The guidelines, developed by the American Heart Association and the American College of Cardiology, lower the starting point for high blood pressure.

Children and young adults with diabetes may have a 7-fold increased risk of sudden cardiac death than those without diabetes.

Rising health care expenditures within the United States has been a major focus of policy makers, business owners, and individuals for years.

Direct-acting oral anticoagulants, alternatives to warfarin, may be less dangerous, but pharmacists still must help keep patients safe.

When pharmacists promote behavioral changes, it encourages positive patterns that last a lifetime.

Having the necessary items will alleviate stress and help attendees have a successful conference.

The sensor that is used along with aripiprazole was first cleared for use by the FDA in 2012; however, the approval of the pill and the sensor together represents a first for the FDA.

President Trump has nominated Alex M. Azar II to be the next secretary of the United States Department of Health and Human Services.

Does this antihyperglycemic combination medication need to be added to a formulary?

In this clip, Eliot A. Brinton, MD, FAHA, FNLA, president of the Utah Lipid Center, discusses how the EMPA-REG trial is a huge step forward for health care providers being able to treat patients with type 2 diabetes with medications that also reduce cardiovascular risk.